Snake venom phospholipases A2: A novel tool against bacterial diseases

Current Medicinal Chemistry

Volumn 19, Issue 36, 2012, Pages 6150-6162

  Samy, R P ^a   Gopalakrishnakone, P ^a   Stiles, B G ^c,d   Girish, K S ^e   Swamy, S N ^f   Hemshekhar, M ^e   Tan, K S ^a,b   Rowan, E G ^h   Sethi, G ^g   Chow, V T K ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d Wilson College   (United States)

^e UNIVERSITY OF MYSORE   (India)

^f SRI JAYACHAMARAJENDRA COLLEGE OF ENGINEERING   (India)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bactericidal activity; Catalytic activity; Gram negative; Gram positive; Lipopolysaccharide (LPS); Phospholipases A2s (PLA2s)

Indexed keywords

4 BROMOPHENACYL BROMIDE; ANTIINFECTIVE AGENT; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BOTHROPSTOXIN I; CALCIUM; DISULFIDE; LIPOPOLYSACCHARIDE; MYOTOXIN I; PHOSPHOLIPASE A2; PHOSPHOLIPID; SNAKE VENOM; SNAKE VENOM PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ALPHA HELIX; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BETA SHEET; BINDING SITE; CATALYSIS; CELL WALL; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME STRUCTURE; INNATE IMMUNITY; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERMEABILITY; PSEUDOMONAS AERUGINOSA; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; BLOOD PROTEINS; CATALYTIC DOMAIN; CELL MEMBRANE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; PHOSPHOLIPASES A2; SNAKE VENOMS;

EID: 84870950297     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804485791     Document Type: Review

References (144)

1. Markland, F. S. Snake venoms and the hemostatic system. Toxicon, 1998, 36, 1749-1800.
2. Fry, B. G. Structure-function properties of venom components from Australian elapids. Toxicon, 1999, 3, 11-32.
3. Panfoli, I.; Calzia, D.; Ravera, S.; Morelli, A. Inhibition of hemorragic snake venom components: Old and new approaches. Toxins, 2010, 2, 417-427.
4. Dhananjava, B. L.; D'Siyza, C. J. The pharmacological role of phosphatases (acid and alkaline phosphomonoesterases) in snake venoms related to release of purines - a multitoxin. Basic Clin. Pharmacol. Toxicol., 2011, 108, 79-83.
5. Mukherjee, A. K.; Ghosal, S. K.; Maity, C. R. Some biochemical properties of Russell's viper (Daboia russelli) venom from Eastern India: correlation with clinico-pathological manifestation in Russell's viper bite. Toxicon, 2000, 38, 163-175.
6. Arid, S. D. Ophidian envenomation strategies and the role of purines. Toxicon, 2002, 40, 335-393.
7. Pornmanee, P.; Sánchez, E. E,; López, G.; Petsom, A.; Khow, O.; Pakmanee, N.; Chanhome, L.; Sangavnich, P.; Pérez, J. C. Neutralization of lethality and proteolytic activities of Malayan pit viper (Calloselasma rhodostoma) venom with North American Virginia opossum (Didelphis virginiana) serum. Toxi - con, 2008, 52, 186-189.
8. Biardi, J. E.; Coss, R. G. Rock squirrel (Spermophilus variegatus) blood sera affects proteolytic and hemolytic activities of rattlesnake venoms. Toxicon, 2011, 57, 323-331.
9. Girish, K. S.; Kemparaju, K. Overlooked issues of snakebite management: Time for strategic approach. Curr. Top. Med. Chem., 2011, 11, 2494-2508.
10. 2. Cardiovasc. Drugs. Ther., 2009, 23, 61-72.
11. 2. Toxicon, 1998, 36, 1623-1633.
12. 2 from snake venoms. Protein Pept. Lett., 2009, 16, 899-907.
13. Six, D. A.; Dennis, E. A. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim. Biophys. Acta., 2000, 1488, 1-19.
14. Schaloske, R. H.; Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta., 2006, 1761, 1246-1259.
15. Burke, J. E.; Dennis, E. A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res., 2009, 50 Suppl, S237-S242.
16. 2. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 175-189.
17. Van Den Bosch, H. Intracellular phospholipases A. Biochim. Biophys. Acta., 1980, 604, 191-246.
18. Gutiérrez, J. M.; Cerdas, L. Mechanism of action of myotoxins isolated from snake venoms. Rev. Biol. Trop. 1984, 32, 213-222.
19. 2 from the venom of the Australian tiger snake (Notechis scutatus scutatus). Arch. Biochem. Biophys. 1995, 318, 481-488.
20. Homsi-Brandeburgo, M. I.; Queiroz, L. S.; Neto, H. S.; Simioni, L. R.; Giglio, J. R. Fractionation of Bothrops jararacussu snake venom: partial chemical characterization and biological activity of bothrops toxin. Toxicon, 1988, 26, 615-627.
21. 2-a structural review. Toxicon, 1996, 34, 827-841.
22. 2 homologues of snake venoms: biological activities and their possible adaptive roles. Protein Pept. Lett., 2009, 16, 860-876.
23. Gutiérrez, J. M.; Lomonte, B. Phospholipase A2 myotoxins from Bothrops snake venoms. Toxicon, 1995, 33, 1405-1424.
24. Ownby, C. L.; Selistre-De-Araujo, H. S.; White, S. P.; Fletcher, J. E. Lysine 49 phospholipase A2 proteins. Toxicon, 1999, 37, 411-445.
25. 2 from Bothrops asper snake venom. Arch. Biochem. Biophys., 1998, 358, 343-350.
26. Nolan, C. J.; Madiraju, M. S.; Delghingaro-Augusto, V.; Peyot, M. L.; Prentki, M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes, 2006, 55 Suppl 2, S16-S23.
27. 2 from bovine pancreas and Crotalus atrox venom. J. Biol. Chem., 1985, 260, 11627-11634.
28. Gopalan, G.; Thwin, M. M.; Gopalakrishnakone, P.; Swaminathan, K. Structural and pharmacological comparison of daboiatoxin from Daboia russelli siamensis with viperotoxin F and vipoxin from other vipers. Acta. Crystallogr. D. Biol. Crystallogr., 2007, 63, 722-729.
29. 2 with homology to the group III bee venom enzyme. J. Biol. Chem., 2000, 275, 7492-7496.
30. 2 isoenzymes. FEBS J., 2005, 272, 1211-1220.
31. 2 isoform isolated from white venom of Crotalus durissus ruruima. Toxicon, 2009, 53, 104-114.
32. Nirthanan, S.; Charpantier, E.; Gopalakrishnakone, P.; Gwee, M. C.; Khoo, H. E.; Cheah, L. S.; Bertrand, D.; Kini, R. M. Candoxin, a novel toxin from Bungarus candidus, is a reversible antagonist of muscle (alphabetagammadelta) but a poorly reversible antagonist of neuronal alpha 7 nicotinic acetylcholine receptors. J. Biol Chem., 2002, 277, 17811-17820.
33. Faure, G.; Xu, H.; Saul, F. A. Crystal structure of crotoxin reveals key residues involved in the stability and toxicity of this potent heterodimeric β-neurotoxin. J. Mol. Biol, 2011, 412, 176-191.
34. Tu, A. T.; Prescott, B.; Chou, C. H.; Thomas Jr, G. J. Structural properties of Mojavetoxin of Crotalus scutulatus (Mojave rattlesnake) determined by laser Raman Spectroscopy. Biochem. Biophys. Res. Comm., 1976, 68, 1139-1145.
35. 2 isolated from the venom of the marine snail Conus magus. J. Biol. Chem., 1995, 270, 3518-3526.
36. Balaji, R. A.; Ohtake, A.; Sato, K.; Gopalakrishnakone, P.; Kini, R. M.; Seow, K. T.; Bay, B. H. λ-Conotoxins, a new family of conotoxins with unique disulfide pattern and protein folding. Isolation and characterization from the venom of Conus marmoreus. J. Biol. Chem., 2000, 275, 39516-39522.
37. 2 myotoxin from Agkistrodon contortrix laticinctus snake venom. Arch. Biochem. Biophys., 1996, 326, 21-30.
38. 2 and their receptors and binding proteins. Biochim. Biophys. Acta., 2000, 1488, 59-70.
39. Fuentes, L.; Hernández, M.; Nieto, M. L.; Sánchez Crespo, M. Biological effects of group IIA secreted phosholipase A2. FEBS Lett., 2002, 531, 7-11.
40. 2 receptor: A regulator of biological functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat., 2002, 68-69, 71-82.
41. 2 activity based on ligand-induced conformational change. J. Biol. Chem., 2005, 280, 7326-7335.
42. Falconi, M.; Desideri, A.; Rufini, S. Membrane-perturbing activity of Viperidae myotoxins: an electrostatic surface potential approach to a puzzling problem. J. Mol. Recognit, 2000, 13, 14-19.
43. 2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon, 2003, 42, 885-901.
44. Calderon, L.; Lomonte, B. Inhibition of the myotoxic activity of Bothrops asper myotoxin II in mice by immunization with its synthetic 13-mer peptide 115-129. Arch. Biochem. Biophys., 1998, 358, 343-350.
45. 49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon, 2001, 39, 1587-1594.
46. 49-phospholipase A2. Biochem. J., 2002, 366, 971-976.
47. 2 reduces its membrane-destabilizing effect. Arch. Biochem. Biophys., 1994, 312, 336-339.
48. 2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/heparan sulfate family. Biochem. Pharmacol, 1994a, 47, 1509-1518.
49. 2 abolishes Ca2+-independent membrane damaging activity. Biochemistry, 2001, 40, 6912-6920.
50. Kini, R. M.; Evans, H. J. A model to explain the pharmacological effects of snake venom phopholipase A2. Toxicon, 1989, 27, 613-635.
51. Hill, C. P.; Yee, J.; Selsted, M. E.; Eisenberg, D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science, 1991, 251, 1481-1485.
52. Hancock, R. E.; Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother, 1999, 43,: 1317-1323.
53. Chen, L.; Kao, P.; Fu, Y.; Lin, S.; Chang, L. Membrane-damaging activity of Taiwan cobra cardiotoxin 3 is responsible for its bactericidal activity. Toxicon, 2011, 58, 46-53.
54. 2 homologue. Proteins, 1998, 30, 442-454.
55. Pedersen, J. Z.; Lomonte, B.; Massoud, R. Gubensek, F.; Gutiérrez, J. M.; Rufini, S. Autocatalytic acylation of phospholipase-like myotoxins. Biochemistry, 1995, 34, 4670-4675.
56. Liu, Q.; Huang, Q.; Teng, M.; Weeks, C. M.; Jelsch, C.; Zhang, R.; Niu, L. The crystal structure of a novel, inactive, lysine 49 PLA2 from Agkistrodon acutus venom. An ultrahigh resolution, ab initio structure determination. J. Biol. Chem., 2003, 278, 41400-41408.
57. 2 in a complex with a transition-state analogue. Science, 1990, 250, 1563-1566.
58. 2-a hypothesis: the crystal structure of piratoxin II complexed to fatty acid. Biochemistry, 2001, 40, 28-36.
59. Francis, B.; Gutiérrez, J. M.; Lomonte, B.; Kaiser, I. I. Myotoxin II from Bothrops asper (Terciopelo) venom is a lysine-49 phospholipase A2. Arch. Biochem. Biophys., 1991, 284, 352-359.
60. Kang, T. S.; Georgieva, D.; Genov, N.; Murakami, M. T.; Sinha, M.; Kumar, R. P.; Kaur, P.; Kumar, S.; Dey, S.; Sharma, S.; Vrielink, A.; Betzel, C.; Takeda, S.; Arni, R. K.; Singh, T. P.; Kini, R. M. Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS J., 2011, 278, 4544-4576.
61. Shimohigashi, Y.; Tani, A.; Matsumoto, H.; Nakashima, K.; Yamaguchi, Y. Lysine-49-PLA2 from Trimeresurus flavoviridis venom are membrane-acting enzymes. J. Biochem., 1995, 118, 1037-1044.
62. 2 from the venom of the cottonmouth snake at 2.0-A resolution. J. Biol. Chem., 1990, 265, 17649-17656.
63. 49-phospholipase A2: biological and membranedisrupting activities in the absence of catalysis. Biochem. J. 2002, 362, 89-96.
64. 2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon 2003, 42, 885-901.
65. 2 as active enzyme for beta-arachidonoyl phospholipid bilayer membranes. Biochem. Mol. Biol. Int., 1997, 43, 19-26.
66. Hancock, R. E.; Lehrer, R. Cationic peptides: a new source of antibiotics. Trends Biotechnol., 1998, 16, 82-88.
67. Broekaert, W. F.; Cammue, B. P. A.; De Bolle, M. F. C.; Thevissen, K.; De Samblanx, G. W.; Osborn, R. W.; Nielson, K. Antimicrobial peptides from plants. Crit. Rev. Plant Sci., 1997, 16, 297-323.
68. Hoffmann, J. A.; Kafatos, F. C.; Janeway, C. A.; Ezekowitz, R. A. Phylogenetic perspectives in innate immunity. Science, 1999, 284, 1313-1318.
69. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415, 389-395.
70. Lüders, T.; Birkemo, G. A.; Fimland, G.; Nissenmeyer, J.; Nes, I. F. Strong synergy between a eukaryotic antimicrobial peptide and bacteriocins from lactic acid bacteria. Applied and Environ. Microbiol., 2003, 69, 1797-1799.
71. 2 enzymes. J. Appl. Microbiol., 2007, 102, 650-659.
72. Perumal Samy, R.; Pachiappan, A.; Gopalakrishnakone, P.; Thwin, M. M.; Hian, Y. E.; Chow, V. T.; Bow, H.; Weng, J. T. In vitro antimicrobial activity of natural toxins and animal venoms tested against Burkholderia pseudomallei. BMC Infect. Dis., 2006, 6, 1-16.
73. Bustillo, S.; Leiva, L. C.; Merino, L.; Acosta, O.; De Kier Joffé, E. B.; Gorodner, J. O. Antimicrobial activity of Bothrops alternatus venom from the Northeast of Argentine. Revista Latinoamericana de Microbiologia, 2008, 50, 79-82.
74. Mosca, R. C.; Do Nascimento, N., An in vitro preliminary study on the growth inhibition of oral microflora by snake venom. J. Dent. Oral Hyg., 2011, 3, 14-118.
75. 2 and L-amino acid oxidase. Toxicon, 2010, 55, 795-804.
76. Samy, R. P.; Gopalakrishnakone, P.; Chow, V. T.; Ho, B. Viper metalloproteinase (Agkistrodon halys pallas) with antimicrobial activity against multidrug resistant human pathogens. J. Cell Physiol., 2008, 216, 54-68.
77. Oguiura, N.; Boni-Mitake, M.; Affonso, R.; Zhang, G. In vitro antibacterial and hemolytic activities of crotamine, a small basic myotoxin from rattlesnake Crotalus durissus. J. Antibiot. (Tokyo), 2011, 64, 327-331.
78. 2 with antibacterial activity from Porthidium nasutum snake venom. Comp. Biochem. Physiol. B.: Biochem. Mol. Biol., 2012, 161, 341-347.
79. 2 enzymes: regulation and physiological role. Biochem. Pharmacol., 1994, 48, 1-10.
80. 2 is linked to macrophage foam cell formation. J. Biol. Chem., 2002, 277, 29116-29124.
81. 2 in inflammatory diseases and trauma. Biochim. Biophys. Acta., 2000, 1488, 83-90.
82. 2. Biochim. Biophys. Acta., 2000, 1488, 71-82.
83. 2): friends or foes? Are they actors in antibacterial and anti-HIV resistance? Med. Clin. (Barc.), 2004, 123, 749-757.
84. 2. Biochim. Biophys. Acta., 2008, 1781, 1-9.
85. 2 is an endogenous antibioticlike protein of the host. Biochimie., 2010, 92, 583-587.
86. 2. J. Immunol., 2001, 166, 4029-4034.
87. 2 is the principal bactericide for Staphylococci and other gram-positive bacteria in human tears. Infect. Immun., 1998, 66, 2791-2797.
88. 2 as a therapeutic target. Biochim. Biophys. Acta., 2000, 1488, 182-187.
89. 2 enzymes. Biochim. Biophys. Acta., 2001, 1533, 29-37.
90. Tseng, A.; Inglis, A. S.; Scott, K. F. Native peptide inhibition. J. Biol. Chem., 1996, 271, 23992-23998.
91. 2, from the venom of Agkistrodon halys pallas. Toxicon, 1987, 25, 401-409.
92. 2 isoform from Crotalus durissus terrificus venom. Toxicon, 2003, 41, 1033-1038.
93. 2 homologue from the venom of the snake Bothrops atrox. Toxicon, 2004, 44, 91-101.
94. 2 from Bothrops neuwiedi pauloensis snake venom. Toxicon, 2004, 44, 305-314.
95. Barbosa, P. S.; Martins, A. M.; Havt, A.; Toyama, D. O.; Evangelista, J. S.; Ferreira, D. P.; Joazeiro, P. P.; Beriam, L. O.; Toyama, M. H.; Fonteles, M. C.; Monteiro, H. S. Renal and antibacterial effects induced by myotoxin I and II isolated from Bothrops jararacussu venom. Toxicon, 2005, 46, 376-386.
96. 2 from Bothrops moojeni snake venom. J. Pharm. Biomed. Anal., 2012, (In press).
97. 2 cDNA from Bothrops jararacussu venom gland. Protein Expression and Purification., 2004, 37, 102-108.
98. 2 homologue: An example of function versatility of snake venom proteins. Comparative Biochemistry and Physiology, Part C., 2006, 142, 371-381.
99. Jacobs, M. R.; Anon, J.; Appelbaum, P. C. Mechanisms of resistance among respiratory tract pathogens. Clin. Lab. Med., 2004, 24, 419-453.
100. Martin, E.; Ganz, T.; Lehrer, R. I. Defensins and other endogenouspeptide antibiotics of vertebrates. J. Leukoc. Biol., 1995, 58, 128-136.
101. Wang, Z.; Wang, G. APD: the Antimicrobial Peptide Database. Nucleic Acids Res., 2004, 32, D590-D592.
102. Hancock, R. E.; Diamond, G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol., 2000, 8, 402-410.
103. Cunliffe, R. N.; Mahida, Y. R. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J. Leukoc. Biol., 2004, 75, 49-58.
104. Bowdish, D. M.; Davidson, D. J.; Lau, Y. E.; Lee, K.; Scott, M. G.; Hancock, R. E. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol., 2005, 77, 451-459.
105. Brown, K. L.; Hancock, R. E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol., 2006, 18, 24-30.
106. 2 from crotalid snake venoms and synthetic peptide variants derived from their C-terminal region. Toxicon, 2005, 45, 807-815.
107. Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol, 2003, 3, 710-720.
108. Boman, H. G. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 1995, 13, 61-92.
109. Won, A.; Ianoul, A. Interactions of antimicrobial peptide from C-terminus of myotoxin II with phospholipid mono-and bilayers. Biochim. Biophys. Acta., 2009, 1788, 2277-2283.
110. Murillo, L. A.; Lan, C. Y.; Agabian, N. M.; Larios, S.; Lomonte, B. Fungicidal activity of a phospholipase-A2-derived synthetic peptide variant against Candida albicans. Rev. Esp. Quimioter., 2007, 20, 330-333.
111. 2 homologues are reduced, but not abolished, by a pH-induced dissociation. Toxicon, 2005, 46, 291-296.
112. 2-like myotoxic component of the Vipera ammodytes meridionalis venomics reveals determinants of myotoxicity and membrane damaging activity. Mol Biosyst, 2012, 8, 1405-1411.
113. 2. J. Biochem., 2002, 131, 285-292.
114. 2. J. Biol Chem., 2002, 277, 5849-5857.
115. 2 by antimicrobial peptides. Antimicrob. Agents Chemother., 2003, 47, 965-971.
116. 2. Annu. Rev. Biochem., 2008, 77, 495-520.
117. Wieprecht, T.; Dathe, M.; Krause, E.; Beyermann, M.; Maloy, W. L.; Mac-Donald, D. L.; Bienert, M. Modulation of membrane activity of amphipathic, antibacterial peptides by slight modifications of the hydrophobic moment. FEBS Lett, 1997, 417, 135-140.
118. 2 from the venom of the Saw-scaled viper: Novel bactericidal and membrane damaging activities. Biochimie., 2010, 92, 1854-1866.
119. 49 myotoxin II-(115-129)-peptide identifies its bactericidal region. Eur. J. Biochem., 1998, 253, 452-461.
120. Gazzano-Santoro, H.; Parent, J. B.; Grinna, L.; Horwitz, A.; Parsons, T.; Theofan, G.; Elsbach, P.; Weiss, J.; Conlon, P. J. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant aminoterminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun., 1992, 60, 4754-4761.
121. 2 from rabbit polymorphonuclear leukocytes. J. Biol Chem., 1979, 254, 11000-11009.
122. 2 in rabbit tears: a host defense against Staphylococcus aureus. Invest. Ophthalmol Vis. Sci., 2001, 42, 2347-2354.
123. Chen, L. W.; Kao, P. H.; Fu, Y. S.; Hu, W. P.; Chang, L. S. Bactericidal effect of Naja nigricollis toxin y is related to its membrane-damaging activity. Peptides, 2011, 32, 1755-1763.
124. Wu, M.; Hancock, R. E. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol Chem., 1999, 274, 29-35.
125. Papo, N.; Shai, Y. Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes?. Peptides, 2003, 24, 1693-1703.
126. Hancock, R. E.; Falla, T.; Brown, M. Cationic bactericidal peptides. Adv. Microbial Phys., 1995, 37, 135-175.
127. 2+ as a regulatory signal. Bioessays, 1998, 20, 96-101.
128. Gunn, J. S.; Ryan, S. S.; Van Velkinburgh, J. C.; Ernst, R. K.; Miller, S. I. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium. Infect. Immun., 2000, 68, 6139-6146.
129. Westerhoff, H. V.; Juretic, D.; Hendler, R. W.; Zasloff, M. Magainins and the disruption of membrane-linked free-energy transduction. Proc. Natl Acad. Sci. U. S. A., 1989, 86, 6597-6601.
130. Yang, L.; Weiss, T. M.; Lehrer, R. I.; Huang, H. W. Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys. J., 2000, 79, 2002-2009.
131. Bierbaum, G.; Sahl, H. G. Induction of autolysis of staphylocci by the basic peptide antibiotics pep5 and nisin and their influence on the activity of autolytic enzymes. Arch. Microbiol, 1985, 141, 249-254.
132. Kao, P. H.; Lin, S. R.; Chang, L. S. Differential binding to phospholipid bilayers modulates membrane-damaging activity of Naja naja atra cardiotoxins. Toxicon, 2009, 54, 321-318.
133. 2 against Gram-positive bacteria. J. Clin. Invest., 1999, 103, 715-721.
134. Thuren, T.; Virtanen, J. A.; Verger, R.; Kinnunen, P. K. Hydrolysis of 1-palmitoyl-2-[6-(pyren-1-yl)]hexanoyl-sn-glycero-3-phospholipids by phospholipase A2: effect of the polar head-group. Biochem. Biophys. Acta., 1987, 917, 411-417.
135. 2: insights into nonelectrostatic molecular determinants by charge reversal mutagenesis. Biochemistry, 1998 37, 6697-6710.
136. Snitko, T.; Koduri, R. S.; Han, S. K.; Othman, R.; Baker, S. F.; Molini, B. J.; Wilton, D. C.; Gelb, M. H.; Cho, W. Mapping the interfacial binding surface of human secretory group IIa phospholipase A2. Biochemistry, 1997, 36, 14325-14333.
137. 2 on mouse endothelial (tEnd) and skeletal muscle (C2C12) cells in vitro. Toxicon, 1999, 37, 145-158.
138. 2 from Bothrops asper snake venom. J. Biol. Chem., 1994b, 269, 29867-29873.
139. 2 from Bothrops asper snake venom. Toxicon, 2001, 39, 879-887.
140. 2 myotoxins and neurotoxins: common aspects of their mechanisms of action. Cell. Mol. Life Sci., 2008, 65, 2897-2912.
141. Wilke M. S.; Lovering, A. L.; Strynadka N. C. J. Beta-lactam antibiotic resistance: a current structural perspective. Current Opinion in Microbiol., 2005, 8, 525-533.
142. Marr, A. K.; Gooderham, W. J.; Hancock, R. E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol., 2006, 6, 468-472.
143. Chiou, Y. L.; Kao, P. H.; Liu, W. H.; Lin, S. R.; Chang, L. S. Roles of lysine residues and N-terminal alpha-amino group in membrane-damaging activity of Taiwan cobra cardiotoxin 3 toward anionic and zwitterionic phospholipid vesicles. Toxicon, 2010, 55, 256-264.
144. Kao, P. H.; Lin, S. R.; Chang, L. S. Differential binding to phospholipid bilayers modulates membrane-damaging activity of Naja naja atra cardiotoxins. Toxicon, 2009, 54, 321-318.